However, HER2 is highly overexpressed in a subset of breast cancers (>106 molecules/cell) [91], and ADCs with optimal combination of targeting antibody, linker, and payload can selectively kill HER2-overexpressing cancer cells while minimizing overt toxicity [92]. Here, ERBB2 is linked to cancer.